Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND)
A legfontosabb adatok
- Ki végzi
- Maimónides Biomedical Research Institute of Córdoba
- Hol
- Spanyolország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 123 fő, tervezett
- Kezdés
- 2025. dec. 1.
- Várható befejezés
- 2027. szept.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
- A regiszteradat frissítve
- 2025. november 28.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults who have had their first stem cell transplant from a donor and carry past CMV infection. They must get letermovir to prevent CMV in the first 100 days. The study only watches and tests blood; it gives no new treatment.
- Életkor
- Over 18 years (record: age >18 years; minimum age 18 Years).
- Nem
- All sexes can join.
- A betegség stádiuma
- First allogeneic (donor) stem cell transplant, from bone marrow, blood or cord blood. Joining must be within the first 28 days after transplant.
- Korábbi kezelés
- Must have a plan for letermovir (LTV) prevention, starting within 28 days after transplant up to 100 days after. Cannot join after a previous donor stem cell transplant; an earlier transplant of your own cells is allowed. Cannot join after ganciclovir, valganciclovir, foscarnet, or high doses of acyclovir, valacyclovir or famciclovir in the 14 days before. Cannot join after cidofovir, CMV hyperimmune immunoglobulin or a trial CMV drug in the 30 days before.
- Biomarker vagy leletérték
- Positive CMV IgG blood test (past CMV infection) at the time of transplant.
A részvétel fő kizáró okai
- Negative CMV IgG test at the time of transplant
- CMV disease in the 6 months before joining, or early CMV treatment needed in the month before
- Known or suspected allergy to letermovir or its ingredients
- Severe liver failure (Child-Pugh class C) or an inborn immune disorder before transplant
- Taking part in a trial of CMV vaccines, other trial CMV drugs or monoclonal antibodies
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Age >18 years
- CMV seropositivity (positive IgG) in the recipient at the time of SCT
- First allogeneic hematopoietic stem cell transplant recipient (bone marrow, peripheral blood, or cord blood)
- Within the first 28 days post-SCT at the time of inclusion
- Indication for LTV prophylaxis within the first 28 days post-transplant up to 100 days post-SCT, according to the criteria established in each center
Ki nem vehet részt
- CMV seronegativity (negative IgG) in the recipient at the time of transplant
- Previous allogeneic stem cell transplant (patients with a prior autologous transplant are allowed to be included)
- History of CMV disease in the 6 months prior to inclusion
- Need for preemptive therapy in the month prior to inclusion in the study
- Received any of the following in the 14 days prior to inclusion: Ganciclovir, valganciclovir, foscarnet, acyclovir (at doses >3200 mg orally per day or >25 mg/kg IV per day), valacyclovir (at doses >3000 mg orally per day), famciclovir (at doses >1500 mg orally per day)
- Received any of the following in the 30 days prior to screening: Cidofovir, CMV hyperimmune immunoglobulin, any CMV antiviral in the investigational phase
- History of primary immunodeficiency prior to transplant
- Participation in a clinical trial involving the administration of CMV vaccines, other investigational CMV drugs, or monoclonal antibodies
- Suspected or confirmed hypersensitivity reaction to the LTV formulation or any of its components
- Severe hepatic insufficiency (defined as Child-Pugh class C)
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (SCT). Fixed-duration letermovir (LTV) prophylaxis during the first 100 days post-SCT is effective and safe in preventing this infection, although it may be associated with a delay in CMV-specific immune reconstitution. Hence, it is needed a study to evaluate whether the absence of CMV-specific immune reconstitution at the end of LTV prophylaxis is associated with the development of late infection. This could facilitate the individualization of CMV prophylaxis duration in these patients.
A teljes eredeti leírásKevesebb
Methods and analysis: INMUNOEND is a multicenter, prospective, observational, non-interventional study including CMV seropositive patients undergoing allo-SCT who receive LTV prophylaxis during the first 100 days post-SCT. Immunological and virological monitorization will be conducted until day +200 post-SCT. The primary outcome variable is the percentage of patients who develop clinically significant CMV infection up to day +200 post-SCT after completing LTV prophylaxis. Data collected will include: baseline characteristics of the hematological diseases and comorbidities, variables related to SCT (i.e. engrafment, graft-versus-host disease, use of letermovir and CMV replication) and variables related to CMV-specific immune reconstitution.
A vizsgálat csoportja
- patients undergoing allogenic-SCT who receive LTV prophylaxis with letermovir
Kezelés: Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in HSCT Recipients (INMUNOEND): a Protocol for a Prospective, Observational, Multicenter Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Publikációk
- A regiszteradat frissítve
- 2025. november 28.